Harel Insurance Investments & Financial Services Ltd. boosted its position in Johnson & Johnson (NYSE:JNJ – Free Report) by 140.0% in the 1st quarter, according to its most recent filing with the SEC. The fund owned 5,968 shares of the company’s stock after purchasing an additional 3,481 shares during the period. Harel Insurance Investments & Financial Services Ltd.’s holdings in Johnson & Johnson were worth $1,457,000 as of its most recent filing with the SEC.
A number of other institutional investors have also recently bought and sold shares of the business. MASTERINVEST Kapitalanlage GmbH lifted its position in shares of Johnson & Johnson by 62.4% in the first quarter. MASTERINVEST Kapitalanlage GmbH now owns 33,629 shares of the company’s stock valued at $8,220,000 after buying an additional 12,918 shares during the last quarter. NFSG Corp increased its holdings in shares of Johnson & Johnson by 7.9% during the 1st quarter. NFSG Corp now owns 7,319 shares of the company’s stock worth $1,789,000 after acquiring an additional 535 shares during the last quarter. Livforsakringsbolaget Skandia Omsesidigt raised its stake in Johnson & Johnson by 1,167.8% in the 1st quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 211,806 shares of the company’s stock valued at $51,761,000 after acquiring an additional 195,100 shares during the period. Northstar Financial Companies Inc. lifted its holdings in Johnson & Johnson by 3.8% during the 1st quarter. Northstar Financial Companies Inc. now owns 11,260 shares of the company’s stock valued at $2,752,000 after purchasing an additional 410 shares during the last quarter. Finally, Ethos Financial Group LLC boosted its position in Johnson & Johnson by 0.6% during the first quarter. Ethos Financial Group LLC now owns 10,442 shares of the company’s stock worth $2,443,000 after purchasing an additional 65 shares during the period. Institutional investors and hedge funds own 69.55% of the company’s stock.
Insider Buying and Selling at Johnson & Johnson
In other news, EVP Kathryn E. Wengel sold 10,000 shares of the stock in a transaction on Thursday, June 11th. The stock was sold at an average price of $241.15, for a total transaction of $2,411,500.00. Following the sale, the executive vice president directly owned 114,288 shares of the company’s stock, valued at approximately $27,560,551.20. This represents a 8.05% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 0.16% of the company’s stock.
Johnson & Johnson News Roundup
- Positive Sentiment: Johnson & Johnson beat Q2 estimates, posting earnings of $2.90 per share on revenue of $25.31 billion, helped by strong growth in Innovative Medicine products such as Darzalex, Tremfya and Spravato. Article Title
- Positive Sentiment: The company raised its 2026 guidance, signaling confidence in continued growth from its pharma pipeline and broader portfolio. Article Title
- Positive Sentiment: Analysts and commentary pointed to momentum beyond legacy drugs, with newer treatments and innovation in medtech and AI-enabled tools supporting the growth story. Article Title
- Neutral Sentiment: J&J also declared its quarterly dividend, reinforcing its appeal as a defensive income stock. Article Title
- Neutral Sentiment: Despite the earnings beat and higher outlook, some reports noted the stock slipped because the market had already priced in strong results and is still weighing mixed MedTech performance and ongoing litigation risk. Article Title
Johnson & Johnson Stock Performance
Shares of NYSE:JNJ opened at $249.70 on Friday. Johnson & Johnson has a 12-month low of $162.30 and a 12-month high of $269.43. The company’s 50 day moving average price is $239.19 and its two-hundred day moving average price is $234.50. The firm has a market cap of $601.08 billion, a PE ratio of 28.93, a PEG ratio of 2.34 and a beta of 0.24. The company has a quick ratio of 0.77, a current ratio of 1.03 and a debt-to-equity ratio of 0.46.
Johnson & Johnson (NYSE:JNJ – Get Free Report) last released its quarterly earnings results on Wednesday, July 15th. The company reported $2.90 earnings per share for the quarter, beating analysts’ consensus estimates of $2.84 by $0.06. The company had revenue of $25.31 billion during the quarter, compared to the consensus estimate of $25.06 billion. Johnson & Johnson had a net margin of 21.48% and a return on equity of 32.86%. The firm’s quarterly revenue was up 6.6% on a year-over-year basis. During the same period in the previous year, the business earned $2.77 earnings per share. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. Equities research analysts predict that Johnson & Johnson will post 11.67 earnings per share for the current year.
Johnson & Johnson Dividend Announcement
The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 8th. Stockholders of record on Tuesday, August 25th will be given a dividend of $1.34 per share. This represents a $5.36 dividend on an annualized basis and a dividend yield of 2.1%. The ex-dividend date is Tuesday, August 25th. Johnson & Johnson’s dividend payout ratio is presently 62.11%.
Wall Street Analysts Forecast Growth
JNJ has been the topic of several research reports. Leerink Partners upgraded shares of Johnson & Johnson from a “market perform” rating to an “outperform” rating and set a $265.00 price objective on the stock in a report on Wednesday, May 13th. The Goldman Sachs Group reaffirmed a “buy” rating and set a $282.00 target price on shares of Johnson & Johnson in a report on Thursday. JPMorgan Chase & Co. increased their price target on shares of Johnson & Johnson from $250.00 to $260.00 and gave the company a “neutral” rating in a report on Wednesday, April 15th. Barclays boosted their price objective on Johnson & Johnson from $234.00 to $255.00 and gave the stock an “equal weight” rating in a report on Wednesday, April 15th. Finally, Royal Bank Of Canada increased their target price on Johnson & Johnson from $265.00 to $287.00 and gave the stock an “outperform” rating in a research note on Monday. Nineteen research analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $265.30.
About Johnson & Johnson
Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.
The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.
Featured Stories
- Five stocks we like better than Johnson & Johnson
- Why Abbott Laboratories Stock Is Suddenly Winning Back Wall Street
- Revving Up Returns: Big Banks Race Through the Rate Plateau
- Why Uber’s Biggest Deal Yet Could Unlock Its Next Growth Phase
- Why Microsoft Is Playing a Different AI Game Than Big Tech—and Cash Flow Is the Test
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
